small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search

Capabilities 83 results

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative healthcare landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Healthcare & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Industry

Financial Crimes Compliance

Winston’s financial crimes compliance lawyers have been providing regulatory compliance counseling and enforcement services related to the Bank Secrecy Act (BSA), the Anti-Money Laundering Act of 2020 (AML), and countering the financing of terrorism (CFT) policy for decades. We also have experience with international AML matters, including in the EU and with respect to Financial Actions Task Force (FATF) recommendations....Read more

Industry

Artificial Intelligence (AI)

Experience 181 results

Experience

|

March 16, 2026

Winston advised La Phocéenne de Cosmétique in connection with the acquisition of Laboratoires de Biarritz.

Winston & Strawn LLP Paris advised La Phocéenne de Cosmétique in connection with the acquisition of Laboratoires de Biarritz....Read more

Experience

|

March 6, 2026

Transition Evergreen & Zencap Agreement: Winston Advises Transition Evergreen on Its Restructuring

Transition Evergreen, a company listed on Euronext Paris and dedicated to ecological transition and carbon-footprint reduction, has completed the first phase of its financial restructuring by carrying out, on February 26 and 27, 2026, the operations set out in a settlement agreement concluded with its main creditor, a private debt fund managed by Zencap Asset Management (“Zencap”)....Read more

Experience

|

March 4, 2026

End of the Line: Winston Wins Unanimous Supreme Court Victory Against NJ Transit

In a unanimous decision authored by Justice Sotomayor, the U.S. Supreme Court held that NJ Transit is not an arm of the State of New Jersey and therefore is not entitled to sovereign immunity. The ruling means that plaintiffs injured by NJ Transit outside of New Jersey—such as in Pennsylvania and New York—may pursue claims in the courts of the states where their injuries occurred. The court adopted Winston’s position that state-created corporations that are formally liable for their own judgments are not arms of the state, reversing the Pennsylvania Supreme Court’s dismissal of Cedric Galette’s negligence suit while affirming the New York Court of Appeals’ decision allowing Jeffrey Colt’s case to proceed....Read more
View All Experience

Insights & News 5,847 results

Capital Markets & Securities Law Watch

|

April 27, 2026

|

4 Min Read

SEC Grants Exemptive Relief for Shortened Equity Tender Offers

On April 16, 2026, the Securities and Exchange Commission’s (the SEC) Office of Mergers and Acquisitions in the Division of Corporation Finance (the Division) issued an exemptive order (the Order) permitting certain tender offers for equity securities to remain open for a minimum of 10 business days rather than the standard 20 business days, subject to strict conditions designed to preserve investor protections.

In the Media

|

April 24, 2026

|

1 Min Read

The American Lawyer Spotlights Winston’s Momentum with Six Partner Additions

Winston was featured in The American Lawyer following the firm’s addition of six lateral partners across Chicago, New York, Washington, D.C., and Dallas in April, further strengthening key practices including leveraged finance, investigations, intellectual property, and appellate litigation....Read more

Recognitions

|

April 17, 2026

|

Less Than 1 Min Read

The Legal 500: Mergers & Acquisitions - France 2026

“France: Mergers & Acquisitions,” appeared in The Legal 500: Mergers & Acquisitions, published by Legalease Ltd. Any opinions in this article are not those of Winston & Strawn or its clients. The opinions in this article are the authors’ opinions only....Read more
View All Insights & News

Other Results 84 results

Law Glossary

What Is the Standard for the FDA to Grant a Generic Drug License?

An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug....Read more

Law Glossary

What Is the Approval Process for Generic Drugs?

Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug....Read more

Law Glossary

What Is a Generic Drug?

Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2026. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising